1. Service Médico-Chirurgical, Valvulopathies - Chirurgie Cardiaque - Cardiologie Interventionnelle Structurelle, Hôpital Cardiologique de Haut Lévèque, Bordeaux, France; 2. Structural Valve Program, Montreal Heart Institute, Montréal, QC, Canada
One half of the patients with severe symptomatic mitral regurgitation (MR) are not referred for surgery, due either to frailty, multiple comorbidities, or prohibitively high surgical risk1,2. The mortality rate in this cohort of patients reaches 50% at five years of follow-up, and up to 90% of surviving patients require hospitalisation for heart failure within five years after the diagnosis of severe MR1,2. In recent years, transcatheter mitral valve repair (TMVr) using the MitraClip® device (Abbott Vascular, Santa Clara, CA, USA) has become a valid and prevalent therapeutic option in patients who are inoperable or deemed to be at high ...
Sign in to read and download the full articleForgot your password?
No account yet? Sign up for free!Create my pcr account
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Read next articleTranscatheter heart valve thrombosis on the mitral stage: “The Tempest” or “Much Ado About Nothing”?